ReviewInnovation (Cambridge (Mass.))2021
Clinical Applications of Serum Anti-Müllerian Hormone Measurements in Both Males and Females: An Update.
Review in Innovation (Cambridge (Mass.)), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Assessment of ovarian dysfunction induced by environmental toxins: a systematic review.Frontiers in public health · 2025Pooled it
- Bibliometric analysis of the research on anti-Müllerian hormone and polycystic ovary syndrome: current status, hotspots, and trends.Frontiers in reproductive health · 2025Pooled it
- Age at menarche and age-adjusted anti-Müllerian hormone level among women of childbearing age in China.Journal of ovarian research · 2026Article
- Impact of anti-Müllerian hormone on pregnancy outcomes in in vitro maturation: a retrospective cohort study.Journal of ovarian research · 2026Article
- Review
- Ovarian intelligence: AI applications leveraging AMH and inhibin B.Frontiers in endocrinology · 2026Review
- Dietary antioxidants and micronutrient status in varicocele-associated male infertility: oxidative stress-mediated effects on semen quality.Frontiers in nutrition · 2026Article
- Associations Between PFAS Exposure and HPG Axis Hormones in U.S. Women.Life (Basel, Switzerland) · 2025Article
- Environmental heavy metal exposure and altering anti-Mullerian hormone levels in women.BMC women's health · 2025Article
- Sex Differences in Cardiovascular Diseases and Vascular Function in Chronic Kidney Disease.Cardiology clinics · 2025Review
- Article
- Optimizing infertility treatment for ovarian endometrioma: is surgical intervention preferable before or after in-vitro fertilization programs?Archives of gynecology and obstetrics · 2025Article
- Body mass index influences Antimüllerian Hormone and inhibin B in adult males.Frontiers in endocrinology · 2025Article
- OvaRePred (HerTempo): an enhanced ovarian aging clock for personalized reserve assessment, endocrine age modeling, and predicting reproductive milestones across the female lifecycle.Frontiers in endocrinology · 2025Article
- Article
- MSCs-derived EVs protect against chemotherapy-induced ovarian toxicity: role of PI3K/AKT/mTOR axis.Journal of ovarian research · 2024Article
- Reduced anti-Müllerian hormone levels in males with inherited bone marrow failure syndromes.Endocrine connections · 2024Article
- Ovarian reserve in children with juvenile idiopathic arthritis using biologic disease-modifying anti-rheumatic drugs.Clinical rheumatology · 2024Article
- Biomarkers of aging.Science China. Life sciences · 2023Review
- An online tool for predicting ovarian responses in unselected patients using dynamic inhibin B and basal antimüllerian hormone levels.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infertility is one of the most common non-communicable diseases, affecting both men and women equally. Ovarian reserve, the number of primordial follicles in the ovaries is believed to be the most important determinants for female fertility. Anti-Müllerian hormone (AMH) secreted from granulosa cells of growing follicles is recognized as the most important biomarker for ovarian reserve. Ovarian reserve models have been developed using AMH and other hormonal indicators, thus childbearing plans and reproductive choices could be arranged by women. In assisted reproductive technology cycles, measurement of AMH helps to predict ovarian response and guide recombinant follicle-stimulating hormone dosing in women. Serum AMH level is increasingly being recognized as a potential surrogate marker for polycystic ovarian morphology, one of the criteria for diagnosis of polycystic ovarian syndrome. AMH is also secreted by Sertoli cells of testes in men, and AMH measurements in the prediction of surgical sperm recovery rate in men have also been investigated. AMH levels are significantly higher in boys than in girls before puberty. Therefore, serum levels of AMH in combination with testosterone is used for the differential diagnosis of disorders of sex development, anorchia, non-obstructive azoospermia, and persistent Müllerian duct syndrome. Recently, serum AMH measurements have also been used in fertility preservation programs in oncofertility, screening for granulosa cell tumors, and prediction of menopause applications. In this review, we will focus on clinical application of AMH in fertility assessments for healthy men and women, as well as for cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.